Dr. Belinda Nedjai is an Associate Professor (Reader) specializing in Cancer Biomarkers and Epigenetics. She also serves as the Director of the Molecular Epidemiology Laboratory within the Wolfson Institute of Population Health (WIPH) at Queen Mary university of London (QMUL).
Dr. Nedjai earned her Ph.D. in Functional Genomics from Queen Mary, Bart's, and the London School of Medicine and Dentistry in London, UK. Her academic journey includes a Master's degree in Cellular and Molecular Physiopathology from the University of Sciences, Pierre et Marie Curie, Paris VI, France, and another Master's degree in Biochemistry with a focus on Immunology and Genetics from the University of Science, Aix Marseille II Luminy, France. She conducted research for 8 years at Imperial College London as post-doctoral researcher and then research Fellow. Her extensive experience spans over 20 years in identifying and validating biomarkers using advanced Next generation sequencing techniques, including Whole Exome Sequencing, Whole Genome Sequencing, Epigenome-Wide Genome Sequencing, RNA sequencing, miRNA analysis, and methylome studies. Her primary research focus is the application of novel quantitative technologies for discovery and validation of DNA methylation biomarkers. One of her notable achievements is the development and validation of DNA methylation assays for triaging women infected with papillomavirus, such as the S5 classifier, which combines DNA methylation of HPV and human genes. This method has been substantially validated in studies worldwide and is considered a gold standard in the field of HPV-related cancers. Dr Nedjai is currently involved in numerous studies focussing on the development of screening and triage molecular tools and algorithms to detect HPV related precancer lesions and cancer early. 
She is dedicated to unraveling genetic and epigenetic pathways in HPV related cancers and working on the development of biomarkers for early cancer detection, accurate diagnosis, and effective cancer management.Dr. Nedjai's laboratory collaborates closely with clinicians, epidemiologists, and statisticians on various clinical trials, exploring innovative screening, diagnostic, and treatment approaches.